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Abstract: 
Background: Selection of resistance mutations may play a major role in the development of 
endocrine resistance. ESR1 mutations are rare in primary breast cancer but have high prevalence in 
patients treated with aromatase inhibitors (AI) for advanced breast cancer. We investigated the 
evolution of genetic resistance to first line AI therapy using sequential ctDNA sampling in patients 
with advanced breast cancer. 
Patients and Methods: 83 patients on first line AI therapy for metastatic breast cancer were 
enrolled in a prospective study. Plasma samples were collected every 3 months to disease 
progression and ctDNA analysed by digital droplet PCR and enhanced tagged-amplicon sequencing 
(eTAm-Seq). Mutations were tracked back through samples prior to progression to study the 
evolution of mutations on therapy. The frequency and impact of KRAS mutations were validated in 
an independent cohort of available baseline plasma samples in the SoFEA study, which enrolled 
patients with prior sensitivity to AI.   
Results: Of the 39 patients who progressed on first line AI, 56.4%(22/39) had ESR1 mutations 
detectable at progression, which were polyclonal in 40.9%(9/22) patients. In serial tracking, ESR1 
mutations were detectable median 6.7 months (95%CI 3.7-NA) prior to clinical progression. 
Utilising eTAm-Seq ctDNA sequencing of progression plasma, ESR1 mutations were demonstrated 
to be sub-clonal in 72.2%(13/18) patients. Mutations in RAS genes were identified in 15.4%(6/39) 
of progressing patients (4 KRAS, 1 HRAS, 1 NRAS). In SoFEA, KRAS mutations were detected in 
21.2%(24/113) of patients, although there was no impact of KRAS mutations on progression free or 
overall survival. 
Conclusions: Cancers progressing on first line AI show high levels of genetic heterogeneity, with 
frequent sub-clonal mutations. Sub-clonal KRAS mutations are found at a high frequency, although 
the detection had no impact on progression on subsequent endocrine therapy in the SoFEA study. 
The genetic diversity of AI resistant cancers may limit subsequent targeted therapy approaches. 
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Key message: 
Breast cancers progressing on first line aromatase inhibitors show high levels of genetic 
heterogeneity, with frequent sub-clonal mutations that may limit subsequent targeted therapy 
approaches. 
Introduction 
Selection of resistance mutations may play a major role in the development of resistance to therapy. 
Many examples are described, such as KRAS mutations emerging in colorectal cancer treated with 
anti-epidermal growth factor receptor (EGFR) therapy (1)(2) and the development of EGFR T790M 
mutations in patients with non small cell lung cancer treated with EGFR inhibitors (3)(4). In breast 
cancer, ESR1 mutations are rare in primary disease (5) but have a high prevalence in patients 
treated with aromatase inhibitor (AI) therapy in the advanced setting. ESR1 mutations mainly occur 
within the ligand binding domain and result in ligand independent activation of the estrogen 
receptor (ER) (6). They are an acquired mechanism of resistance and mutations in ctDNA predict 
resistance to AI (7)(8). In a retrospective study (9), circulating ESR1 mutations were found in 
30.6% of patients at progression on an AI and were detectable in 75% of those patients prior to 
progression.  
 
We investigated the development and evolution of genetic resistance to first line AI therapy in a 
prospective study using sequential ctDNA sampling in patients with advanced breast cancer.  
Samples were analysed with ESR1 multiplex droplet digital PCR (ddPCR) assays and by enhanced 
tagged-amplicon sequencing (eTAm-Seq, InVision™) to investigate for mutations that may 
contribute to AI resistance. Sub-clonal KRAS mutations were found relatively frequently in ctDNA of 
patients progressing on first line AI therapy, suggesting that KRAS mutations could be selected as a 
potential mechanism of resistance. We validated the frequency of KRAS mutations in baseline 
plasma of the SoFEA study, a large phase III trial of patients who had progressed on prior AI 
therapy.  
 
Materials and Methods 
Study Design 
Eighty-three patients on first line AI therapy for metastatic breast cancer were enrolled in the 
prospective plasmaDNA AI study (CCR3297, REC 10/H0805/50) to collect plasma samples for 
ctDNA analysis every three months on therapy, and at disease progression. All plasma samples 
were analysed with ESR1 multiplex ddPCR assays, and samples at disease progression were 
analysed by eTAm-Seq. Mutations identified by eTAm-Seq were tracked back through samples prior 
to disease progression, to study the evolution of mutations on therapy. Written informed consent 
was obtained from all patients.  
 
ER, progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2) were 
assessed in a single laboratory at the Royal Marsden Histopathology department (or reviewed by 
the RMH when reported from a referring hospital) using standard criteria. 
 
Plasma collection and processing 
In the plasmaDNA AI study, plasma samples were collected every 3 months and at end of treatment 
in EDTA Blood Collection Tubes (BCT).  Samples were processed within 2 hours of collection by 
centrifugation at 1600g for 20 minutes at room temperature.  Plasma was separated from buffy 
coat and red blood cells, aliquoted and stored at -80oC until DNA extraction.  
 
In the SoFEA trial, baseline blood was collected in EDTA BCT and processed within 0 to 9 days of 
sample collection. Plasma was separated by centrifugation 1600g for 20 minutes. We have 
previously demonstrated that archival EDTA plasma samples can be used for ctDNA analysis with 
ddPCR (8). 
 
DNA extraction 
Following thawing, ctDNA was extracted from 2 or 4ml of plasma using the MagMax Cell-Free DNA 
Isolation kit (Thermo A29319) on a Kingfisher Flex Purification System (Thermo) according to 
manufacturer instructions. The DNA was quantified and stored at -20oC until analysis.  
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Droplet digital PCR  
DNA concentration was estimated in each sample as previously described (7). 
For ESR1 mutation analysis we used two commercially available ddPCR multiplexes from Bio-Rad, 
multiplex 1 (dHsaMDXE91450042) and multiplex 2 (dHsaMDXE65719815). Multiplex 1 contained 
FAM-labelled probes for E380Q (c.1138G>C), L536R (c.1607T>G), Y537C (c.1610A>G), D538G 
(c.1613A>G). Multiplex 2 contained FAM-labelled probes for S463P (c.1387T>C), Y537N 
(c.1609T>A) and Y537S (c.1610A>C).   
For KRAS mutation analysis we used a commercially available ddPCR multiplex from Bio-Rad (Cat 
Number 1863506). The multiplex assay contains FAM-labelled probes to 7 commonly occurring 
hotspot mutations on codons 12 and 13 of KRAS. 
Samples were analyzed using DNA extracted from 1 ml plasma (1ml plasma equivalent). Multiplex 
reaction volumes were made up to 20μl with 10μl of Bio-Rad ddPCR Supermix for probes, 1μl of 
assay and 9μl nuclease-free water, then partitioned to a mean of 15,000 droplets using a ddPCR 
Auto Droplet Generator (Bio-Rad). For ESR1 mutation analysis the following conditions were used: 
95oC for 10 minutes followed by 40 cycles of 95oC for 15 seconds then 52oC for 60 seconds, ramp 
rate 2.5oC/second, and final incubation 98oC for 10 minutes. For KRAS mutation analysis the 
following conditions were used: 95oC for 10minutes followed by 40 cycles of 94oC for 30 seconds 
then 55oC for 60 seconds, ramp rate 2.5oC/second, and final incubation 98oC for 10 minutes.  The 
subsequent analysis was done on a Bio-Rad QX200 droplet reader, and analyzed using QuantaSoft 
software v1.7.4.0917 (Bio-Rad).  A multiplex assay was called as mutation positive if there were at 
least 2 FAM-positive droplets.  Samples were only called negative if there were at least 300 wild 
type alleles detected and <2 FAM-positive droplets.  If this criterion was not met the sample was 
repeated or failed if there was insufficient material to repeat.   
 
InVision™ / eTAm-Seq analysis 
The InVision liquid biopsy platform combines efficient next-generation sequencing library 
preparation and statistical algorithms to identify and quantify low frequency tumor-derived single 
nucleotide variants (SNVs), insertions/deletion (Indels) and CNVs in cell-free DNA, based on 
methods previously described (10)(3).. Next generation sequencing libraries were prepared using a 
two-step amplification process, with primers targeting 36 cancer-related genes (Supplementary 
figure 1) designed to hotspot and entire coding regions of interest. The panels (v1.4/v1.5) are 
optimised for amplification of highly fragmented DNA with amplicon sizes ranging 72bp –154bp. 
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Pooled libraries were quantified using Kapa Library Quantification Kit, and 1.8pM libraries 
analysed on an Illumina NextSeq 500 (300 cycle PE). Sequencing files were analysed using the 
Inivata Somatic Mutation Analysis (ISoMA) analytical pipeline (V1.15-1.17), and sequencing reads 
clipped, merged and aligned. Coding and splice-site mutations in SNVs and Indels were annotated 
using Variant Effect Predictor (VEP) using the canonical transcript for each gene. Sub-clonal 
mutations were defined as mutations with an aggregate allele frequency <0.25 of driver mutation 
allele frequency identified in the analyzed samples. 
Orthogonal validation of the detected mutations by eTAm-Seq was performed using ddPCR as 
described above. KRAS, PIK3CA and TP53 mutations were validated using either commercially 
available assays or in-house designed assays as previously described (11). 
 
Statistical analysis  
All statistical analysis was performed with GraphPad Prism version 6.0, Stata or R. Lead time was 
calculated using the Turnbull estimator. For analyses of progression free survival (PFS), Kaplan-
Meier curves were plotted and groups compared using the log-rank test. 
Results 
 
ESR1 mutations are frequently subclonal and polyclonal at progression on AI 
83 patients with ER positive metastatic breast cancer on 1st line AI therapy were enrolled into a 
prospective study to collect plasma samples for ctDNA analysis every 3 months and at disease 
progression (Figure 1A). The clinical and pathological characteristics of the study cohort are 
described in Figure 1B. 
 
We initially studied the evolution of ESR1 mutations on AI therapy, using ultra high sensitivity 
multiplex ddPCR assays for 7 commonly occurring ESR1 mutations to track these mutations in 
plasma until clinical progression. Of the 39 patients who progressed on first line AI, 56.4% (22/39) 
had ESR1 mutations detectable at progression. In the patients with ESR1 mutations detected, the 
mutations were polyclonal in 40.9% (9/22) of patients (Figure 2). In serial tracking prior to 
progression, ESR1 mutations were detectable in plasma prior to progression in 86.4% (19/22) of 
patients, with ESR1 mutations detectable a median of 6.7 months (95% CI 3.7-NA) prior to clinical 
progression (Figure 4). In patients who progressed on AI, all patients who had ESR1 mutations 
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detected prior to progression also had ESR1 mutations detected at progression, suggesting the early 
detection of ESR1 mutations robustly predicted the presence of the mutation at progression.  ESR1 
mutations were detectable in 15.2% (5/33) patients who had not yet clinically progressed (Figure 
1B). 
 
AI resistant breast cancers are genomically diverse 
We investigated the genetics of breast cancers progressing on first line AI, with eTAm-Seq deep 
sequencing of ctDNA from progression plasma samples. Consistent with other studies (5) (12) (13), 
TP53 (36.1% (13/36)), ESR1 (33.3% (12/36)) and PIK3CA (25.0% (9/36)) mutations were the 
most frequent mutations detected. ESR1 mutations were identified in more samples by ddPCR than 
by eTAm-Seq. Of the 10 discordant cases, one ESR1 mutation detected by eTAm-Seq but not ddPCR 
occurred at an allele fraction (AF) of 0.002, whereas 9 ESR1 mutations detected only by ddPCR 
occurred at AF’s ranging from 0.0004 to 0.032. For 1 case, there was weak evidence of an ESR1 
mutation but this was below the eTAm-Seq calling threshold. These cases had lower mutant copies 
per ml in ddPCR compared to concordant cases (median 14.3 vs 51.5 respectively, p=0.048 Mann 
Whitney U Test), suggesting that ddPCR was detecting low levels of ESR1 mutation in ctDNA. In 
patients with additional driver mutations detected in ctDNA, ESR1 mutations were sub-clonal in 
72.2% (13/18) of the patients (Figure 2), found at aggregate relative allele frequency <0.25, with 
ESR1 mutation diversity increasingly detectable at the point of progression compared to samples 
taken prior to progression (Figure 2). In patients with polyclonal mutations, individual mutations 
were observed to be on different DNA strands in eTAm-Seq, further supporting the sub-clonality of 
the observed ESR1 mutations.  
 
Deep ctDNA sequencing of progression samples identified previously unrecognized genetic 
diversity. Polyclonal KRAS mutations were identified in two patients, 8005 (p.G12V, p.G12S) and 
8023 (p.G12V, p.G12C, p.G12R), a monoclonal HRAS mutation (p.G12V) in one patient and a 
monoclonal NRAS mutation (p.G12D) in another one. An activating p.R248C FGFR3 mutation was 
identified in a further patient ctDNA sample. Deep sequencing or ddPCR of ctDNA obtained from 
plasma identified RAS mutations in 15.4% (6/39) of progressing patients (4 KRAS (2 of which were 
polyclonal), 1 monoclonal HRAS and 1 monoclonal NRAS) (Figure 5). In patients where an 
additional driver mutation was detected in ctDNA, all identified RAS mutations were sub-clonal.  In 
two patients with KRAS mutations detected at progression primary tumour was available, with the 
KRAS mutation being undetectable in both patients. 
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Clonal Haematopoesis of Indeterminate Potential (CHIP) is an age related clonal expansion that is 
detectable in a high proportion of ageing people (14) (15).  Mutations arising from CHIP may be 
detected in ctDNA analysis and present a potential confounder to discovery of resistance mutations 
in ctDNA. Although KRAS mutations are not a classic CHIP mutation, they are reported at low level. 
To ascertain whether detected KRAS mutations were arising from ctDNA or CHIP, we tracked KRAS 
mutations back through serial samples prior to progression (Figure 5). KRAS mutations arose in 
line with driver and ESR1 mutations at disease progression, demonstrating that the KRAS mutations 
were detected in ctDNA. In contrast, a TP53 mutation detectable at progression was shown to arise 
from CHIP with high-likelihood, as the AF of the mutation stayed constant through serial tracking, 
whilst mutations arising from ctDNA rose to the point of progression (Figure 2).  
 
Identified RAS mutations are selected on AI therapy 
To validate our novel discovery of KRAS mutations in AI resistant cancer, and to assess clinical 
significance of KRAS mutations in patients who progressed on endocrine therapy, we analysed 
baseline plasma samples from the phase III SoFEA study by ddPCR. The SoFEA study was a 
multicentre, randomized phase III trial in postmenopausal women with advanced, hormone 
receptor positive breast cancer who had progressed on a non-steroidal AI. All patients had 
demonstrated prior sensitivity to AIs, and were randomized to fulvestrant plus anastrozole, 
fulvestrant plus placebo, or exemestane.  
 
We retrospectively analysed KRAS mutational status on 117 available baseline plasma samples of 
the 723 patients enrolled on the study. We investigated the association of KRAS mutations detected 
in ctDNA and clinical outcome. These samples had previously been analysed for ESR1 mutation 
status (8). KRAS mutational status was successfully interrogated in 96.6% (113/117) of available 
plasma samples, with KRAS mutations detected in 21.2% (24/113) of patients, with no KRAS 
mutations detected in controls (Supplementary table 2). 19.0% (8/42) of ESR1 mutant cancers also 
had KRAS mutations. KRAS mutations were detected at low levels in the majority of patients. There 
were no significant differences in baseline characteristics between patients with and without KRAS 
mutations (Supplementary table 3). 
We assessed the impact of KRAS mutations on progression free and overall survival (Figure 6). For 
patients with KRAS mutations the median PFS was 3.7 months (95% CI, 2.7, 11.5) and for patients 
with wild type KRAS a median PFS of 4.6 months (95% CI, 3.0, 6.5) (HR=1.04 95% CI (0.65, 1.67) 
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p=0.86). There was no significant difference in overall survival in those with and without KRAS 
mutations.  
 
Discussion 
In the prospective plasmaDNA AI study we demonstrate that ER positive advanced breast cancer 
progressing on AI shows substantial genetic diversity, with a high rate of ESR1 mutations and previ 
mutations in KRAS and a classical activating mutation in FGFR3. Many selected mutations are 
demonstrated to be sub-clonal, although our findings identify a potential major role for selected 
KRAS mutations in resistance to AI therapy in the treatment of advanced breast cancer. 
 
In this cohort of patients progressing on first line AI, ESR1 mutations are found at high prevalence 
in plasma, detectable in over half of patients. Resistance to therapy can be anticipated with a long 
lead-time over clinical progression, with ESR1 mutations detectable prior to progression in 86.4% 
of patients. These results are consistent with a prior retrospective study that reported ESR1 
mutations were detectable in 75% of patients prior to progression (9).  This prior study reported a 
lower frequency of ESR1 mutations at progression on an AI but only 4 ESR1 mutations were 
analysed using 4ng preamplified DNA which likely explains the higher frequency reported here. The 
incidence of ESR1 mutations we report is in line with the rate we previously reported in the SoFEA 
study, with ESR1 mutations detected in 39.1% of baseline samples (8).  
 
We show that many ESR1 mutations detected in plasma are likely sub-clonal in the cancer, with the 
aggregate allele fraction of ESR1 mutations frequently substantially lower than that of other 
identified driver mutations. This suggests that in an individual patient, ESR1 mutations may not be 
the sole driver of resistance in the cancer. Multiple drugs that degrade the mutant ER are in early 
clinical, and pre-clinical development, and this finding emphasises the importance of assessing 
clonal dominance of ESR1 mutations in clinical development. Also, due to the sub-clonal nature of 
these mutations, the amount of plasma DNA analysed may have a major impact on frequencies of 
ESR1 mutations identified.  
 
In this study, we identify selection of KRAS activating mutations as a potential novel mechanism of 
resistance to AI, with a substantial prevalence of 21.2% (24/113) in the SoFEA validation series. 
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KRAS mutations are identified in approximately 2% of primary ER positive breast cancer (5) (12), 
and KRAS mutations are undetectable in the primary of two patients with selected KRAS mutations, 
suggesting selection by therapy.  The KRAS mutations identified are frequently sub-clonal, possibly 
due to geographic development of KRAS mutations in individual metastases. Multiple prior studies 
have linked activation of MAP kinase pathway signaling to resistance to endocrine therapy (16, 17), 
suggesting the KRAS mutations may drive resistance to endocrine therapy in individual sub-clones. 
In SoFEA the presence of a KRAS mutation detected in ctDNA had no impact on PFS or OS, although 
this analysis used a relatively small number of samples and would need confirmation in a larger set. 
This finding suggests the importance of determining whether sub-clonal KRAS mutations continue 
to expand through subsequent therapy, or whether the mutations become undetectable once 
endocrine therapy is ceased, which will be an important area of future research.  
 
This study has limitations. Some patients joined the study mid-AI therapy and had ESR1 mutations 
detected at the first sample. Although, this was taken into account when calculating lead time to 
progression, this adds imprecision to the median estimate of lead-time. There were a relatively 
small number of progression samples in the plasma AI study and it was not possible to perform 
sequencing on all progression samples due to amounts of DNA available. Although the ctDNA 
sequencing strategy we employ substantially expanded our ability of investigate the genetics of AI 
resistant cancer, leading to the discovery of KRAS mutations, the panel covered a limited number of 
genes. There may be other relevant selected mutations present at progression on AI that were not 
detected in this panel. Most of the KRAS mutations detected were present at low levels, and 
although some mutations were present at relatively high level it was not possible due to limited 
number of high level mutations to assess whether there is a different impact on outcome for those 
with high levels of KRAS mutation. 
 
Our study demonstrates that selected genetic mechanisms of resistance are frequent in first line AI 
therapy. ESR1 mutations are found at high prevalence in this setting, along with high frequency sub-
clonal KRAS mutations. AI resistant cancers are genetically heterogeneous and may consist of 
several clones that may limit the effectiveness of subsequent targeted therapies that target only one 
of the clones. 
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